TY - JOUR
T1 - Pleural infection
T2 - Past, present, and future directions
AU - Corcoran, John P.
AU - Wrightson, John M.
AU - Belcher, Elizabeth
AU - DeCamp, Malcolm M.
AU - Feller-Kopman, David
AU - Rahman, Najib M.
N1 - Funding Information:
JPC is study coordinator for PILOT (ISRCTN 50236700), an observational study of pleural infection funded by the Medical Research Council, UK. DF-K has provided consultancy services to Spiration, Inc. NMR has provided consultancy services for Rocket Medical UK and was corresponding author for the MIST2 study, which was supported by an unrestricted educational grant from Roche UK to the University of Oxford. NMR is also chief investigator for the PILOT study and is director of the University of Oxford Respiratory Trials Unit that published the MIST1 and MIST2 studies. JMW, EB, and MMDC declare no competing interests.
Funding Information:
No external funding was sought or needed for the production of this article. JMW and NMR are funded by the National Institute of Health Research Oxford Biomedical Research Centre.
Publisher Copyright:
© 2015 Elsevier Ltd.
PY - 2015/7
Y1 - 2015/7
N2 - Pleural space infections are increasing in incidence and continue to have high associated morbidity, mortality, and need for invasive treatments such as thoracic surgery. The mechanisms of progression from a non-infected, pneumonia-related effusion to a confirmed pleural infection have been well described in the scientific literature, but the route by which pathogenic organisms access the pleural space is poorly understood. Data suggests that not all pleural infections can be related to lung parenchymal infection. Studies examining the microbiological Prof.ile of pleural infection inform antibiotic choice and can help to delineate the source and pathogenesis of infection. The development of radiological methods and use of clinical indices to predict which patients with pleural infection will have a poor outcome, as well as inform patient selection for more invasive treatments, is particularly important. Randomised clinical trial and case series data have shown that the combination of an intrapleural tissue plasminogen activator and deoxyribonuclease therapy can potentially improve outcomes, but the use of this treatment as compared with surgical options has not been precisely defined, particularly in terms of when and in which patients it should be used.
AB - Pleural space infections are increasing in incidence and continue to have high associated morbidity, mortality, and need for invasive treatments such as thoracic surgery. The mechanisms of progression from a non-infected, pneumonia-related effusion to a confirmed pleural infection have been well described in the scientific literature, but the route by which pathogenic organisms access the pleural space is poorly understood. Data suggests that not all pleural infections can be related to lung parenchymal infection. Studies examining the microbiological Prof.ile of pleural infection inform antibiotic choice and can help to delineate the source and pathogenesis of infection. The development of radiological methods and use of clinical indices to predict which patients with pleural infection will have a poor outcome, as well as inform patient selection for more invasive treatments, is particularly important. Randomised clinical trial and case series data have shown that the combination of an intrapleural tissue plasminogen activator and deoxyribonuclease therapy can potentially improve outcomes, but the use of this treatment as compared with surgical options has not been precisely defined, particularly in terms of when and in which patients it should be used.
UR - http://www.scopus.com/inward/record.url?scp=84943147080&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943147080&partnerID=8YFLogxK
U2 - 10.1016/S2213-2600(15)00185-X
DO - 10.1016/S2213-2600(15)00185-X
M3 - Review article
C2 - 26170076
AN - SCOPUS:84943147080
VL - 3
SP - 563
EP - 577
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
SN - 2213-2600
IS - 7
ER -